Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR) can stop therapy without relapsing. | Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
